BRAF
Apr 17 2026
FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
Read more
BRAF
Apr 17 2026
Clinical activity and safety of novel BRAF inhibitor Plixorafenib (FORE8394) in BRAF V600-mutated advanced colorectal cancers (CRC) r1,
Read more
BRAF
Nov 10 2025
Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF-mutated primary and brain metastatic melanoma
Read more
BRAF
Sep 16 2025
Clinical Activity and Safety of Novel BRAF Inhibitor Plixorafenib (FORE8394; PLX8394) in Advanced TC Harboring BRAF Alterations
Read more
BRAF
Sep 16 2025
Effect of Food & Cobicistat Administration on the Pharmacokinetics & Safety of Plixorafenib in Healthy Participants
Read more
BRAF
May 31 2025
FORTE: A phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers
Read more
BRAF
Apr 25 2025
Circulating tumor DNA analysis in patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in Phase 1/2a study
Read more
BRAF
Apr 25 2025
FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers
Read more
BRAF
Oct 21 2024
Activity of BRAF Inhibitor Plixorafenib (FORE8394) in Advanced Ovarian Cancer Harboring BRAF V600E Mutation
Read more
BRAF
Oct 17 2024
Safety & Efficacy of BRAF Inhibitor Plixorafenib in Children & Adults with Recurrent, BRAF altered PCNSTs
Read more